2026-04-17T06:25:12Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/124222025-10-24T10:40:30Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc YUSTE GUTIERREZ, ANGEL MANUEL author Alonso Moreno, Marta author Perez Blanco, Jose Luis author Peña Fernandez, Maria Angeles author Perez Maroto, Maria Teresa author David, Berlana author 2025-01-16T08:42:50Z 2025-01-16T08:42:50Z 2024-11-16 Ferric carboxymaltose; Iron deficiency anemia; Iron intravenous administration Carboximaltosa férrica; Anemia ferropénica; Administración intravenosa de hierro Carboximaltosa fèrrica; Anèmia ferropènica; Administració intravenosa de ferro Aim: Anemia, primarily due to iron deficiency, is a key risk factor in both elective and emergency surgeries. Immediate preoperative treatment with ferric carboxymaltose (FCM) in anemic patients can reduce the need for transfusions and the length of hospital stay, thereby optimizing surgical outcomes. The objective of this study was to assess the effectiveness and describe the use of administering intravenous FCM prior to elective scheduled surgery for patients diagnosed with anemia. Methods: Multicenter, retrospective cohort study that encompassed patients aged 18 years and older who underwent surgery between January 2017 and December 2018. Demographic variables, dose scheme, baseline and perioperative haemoglobin (Hb), transfusion requirements, and admission days were collected. The primary endpoints were the response rate and effectiveness of FCM, defined as the proportion of patients with Hb preoperative levels of ≥ 13 g/dL. A patient response was deemed to occur when Hb level increased by 1 g/dL or more. The secondary endpoints were the appropriateness of FCM dose, transfusion requirement rate, and length of hospital stay. Results: 446 patients (55.2% women, median age 69 IQR:52– 78 years) were included. The median total dose of FCM administered was 1000 mg over a span of 5 day (IQR: 0– 16) days before surgery. 62.8% of patients received lower doses, 24.9% had an INCREASE of Hb ≥ 1 g/dL, 11.6% had Hb ≥ 13 g/dL and 21.3% required blood transfusions, with a mean of 0.73 units transfused. The length of the hospital stay was 12 days (IQR:6– 23). Conclusion: Low percentage of patients achieved a hemoglobin level of 13 g/dL or experienced an increase in hemoglobin of 1 g/dL or more following the administration of FCM, indicating the low effectiveness of FCM in treating perioperative anaemia in our surgical patients. There is underdosing of FCM and insufficient time between FCM administration and surgery in most patients. Both transfused and non-transfused patients show similar Hb increases, while those receiving a standard 1000 mg dose of FCM experience shorter hospital stays compared to those receiving 500 mg, and patients with more transfusions have longer hospital stays. http://hdl.handle.net/11351/12422 Anèmia ferropènica - Tractament Ferro - Ús terapèutic Cirurgia - Complicacions Avaluació de resultats (Assistència sanitària) DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Metals, Heavy::Iron Other subheadings::Other subheadings::/therapeutic use ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Patient Care::Perioperative Care ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::metales pesados::hierro Otros calificadores::Otros calificadores::/uso terapéutico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::asistencia al paciente::asistencia periquirúrgica TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Use and Effectiveness of Carboximaltose Iron in Preoperative Anemia Treatment: A Multicenter and Retrospective Study